CY1122758T1 - Μεθοδος για παρασκευη υδροχλωρικης 1-(4-(4-(3,4-διχλωρο-2-φθοροφαινυλαμινο)-7-μεθοξυκιναζολιν-6-υλοξυ)πιπεριδιν-1-υλο)-προπ-2-εν-1-ονης και ενδιαμεσων που χρησιμοποιουνται σε αυτη - Google Patents
Μεθοδος για παρασκευη υδροχλωρικης 1-(4-(4-(3,4-διχλωρο-2-φθοροφαινυλαμινο)-7-μεθοξυκιναζολιν-6-υλοξυ)πιπεριδιν-1-υλο)-προπ-2-εν-1-ονης και ενδιαμεσων που χρησιμοποιουνται σε αυτηInfo
- Publication number
- CY1122758T1 CY1122758T1 CY20201100214T CY201100214T CY1122758T1 CY 1122758 T1 CY1122758 T1 CY 1122758T1 CY 20201100214 T CY20201100214 T CY 20201100214T CY 201100214 T CY201100214 T CY 201100214T CY 1122758 T1 CY1122758 T1 CY 1122758T1
- Authority
- CY
- Cyprus
- Prior art keywords
- methoxyquinazolin
- fluorophenylamino
- yloxy
- piperidin
- prop
- Prior art date
Links
- 239000000543 intermediate Substances 0.000 title abstract 2
- OMYSOLOMWJFVNK-UHFFFAOYSA-N 1-[4-[4-(3,4-dichloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl]oxypiperidin-1-yl]prop-2-en-1-one;hydrochloride Chemical compound Cl.C=12C=C(OC3CCN(CC3)C(=O)C=C)C(OC)=CC2=NC=NC=1NC1=CC=C(Cl)C(Cl)=C1F OMYSOLOMWJFVNK-UHFFFAOYSA-N 0.000 title 1
- 102000001301 EGF receptor Human genes 0.000 abstract 2
- 108060006698 EGF receptor Proteins 0.000 abstract 2
- 206010059866 Drug resistance Diseases 0.000 abstract 1
- 206010071990 Tyrosine kinase mutation Diseases 0.000 abstract 1
- 230000005907 cancer growth Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000002018 overexpression Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020110101422A KR101272613B1 (ko) | 2011-10-05 | 2011-10-05 | 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온 염산염의 제조 방법 및 이에 사용되는 중간체 |
| PCT/KR2012/008077 WO2013051883A2 (en) | 2011-10-05 | 2012-10-05 | Method for preparing 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)-prop-2-en-1-one hydrochloride and intermediates used therein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1122758T1 true CY1122758T1 (el) | 2021-03-12 |
Family
ID=48044309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20201100214T CY1122758T1 (el) | 2011-10-05 | 2020-03-11 | Μεθοδος για παρασκευη υδροχλωρικης 1-(4-(4-(3,4-διχλωρο-2-φθοροφαινυλαμινο)-7-μεθοξυκιναζολιν-6-υλοξυ)πιπεριδιν-1-υλο)-προπ-2-εν-1-ονης και ενδιαμεσων που χρησιμοποιουνται σε αυτη |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8859767B2 (enExample) |
| EP (2) | EP2763981B1 (enExample) |
| JP (1) | JP5805880B2 (enExample) |
| KR (1) | KR101272613B1 (enExample) |
| CN (2) | CN110003174A (enExample) |
| AU (1) | AU2012319291B2 (enExample) |
| BR (1) | BR112014007718B1 (enExample) |
| CA (1) | CA2850055C (enExample) |
| CY (1) | CY1122758T1 (enExample) |
| DK (1) | DK2763981T3 (enExample) |
| ES (1) | ES2775197T3 (enExample) |
| HR (1) | HRP20200426T1 (enExample) |
| HU (1) | HUE048798T2 (enExample) |
| IL (3) | IL231911B (enExample) |
| IN (1) | IN2014DN03447A (enExample) |
| LT (1) | LT2763981T (enExample) |
| MX (1) | MX348815B (enExample) |
| PL (1) | PL2763981T3 (enExample) |
| PT (1) | PT2763981T (enExample) |
| RS (1) | RS60118B1 (enExample) |
| RU (1) | RU2563630C1 (enExample) |
| SI (1) | SI2763981T1 (enExample) |
| WO (1) | WO2013051883A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101317809B1 (ko) | 2011-06-07 | 2013-10-16 | 한미약품 주식회사 | 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물 |
| KR20140096571A (ko) * | 2013-01-28 | 2014-08-06 | 한미약품 주식회사 | 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법 |
| CN104513229A (zh) * | 2013-09-28 | 2015-04-15 | 正大天晴药业集团股份有限公司 | 喹唑啉衍生物及其制备方法 |
| HK1244278B (zh) | 2015-03-20 | 2020-04-17 | 正大天晴药业集团股份有限公司 | 喹唑啉衍生物的盐及其制备方法 |
| KR102802129B1 (ko) * | 2018-09-14 | 2025-05-02 | 한미약품 주식회사 | 퀴나졸린 화합물 및 이의 염산염의 결정 형태 |
| KR101950942B1 (ko) * | 2019-01-28 | 2019-02-22 | 한미약품 주식회사 | 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법 |
| US20210221792A1 (en) * | 2020-01-16 | 2021-07-22 | Hanmi Pharm Co., Ltd. | Convergent synthesis of poziotinib derivative |
| WO2022043923A1 (en) * | 2020-08-28 | 2022-03-03 | Hanmi Science Co., Ltd. | Synthesis of poziotinib derivative |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200813014A (en) * | 2002-03-28 | 2008-03-16 | Astrazeneca Ab | Quinazoline derivatives |
| DE602004004811T2 (de) * | 2003-09-19 | 2007-11-22 | Astrazeneca Ab | Chinazolinderivate |
| GB0322409D0 (en) * | 2003-09-25 | 2003-10-29 | Astrazeneca Ab | Quinazoline derivatives |
| EP1966189A1 (de) * | 2005-12-12 | 2008-09-10 | Boehringer Ingelheim International Gmbh | Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| TWI377944B (en) * | 2007-06-05 | 2012-12-01 | Hanmi Holdings Co Ltd | Novel amide derivative for inhibiting the growth of cancer cells |
| CN102459174A (zh) * | 2009-04-23 | 2012-05-16 | 阿斯利康(瑞典)有限公司 | 4-(3-氯-2-氟苯胺基)-7-甲氧基-6-[1-(n-甲基氨基甲酰基甲基)哌啶-4-基]喹唑啉的制备方法 |
-
2011
- 2011-10-05 KR KR1020110101422A patent/KR101272613B1/ko not_active Expired - Fee Related
-
2012
- 2012-10-05 SI SI201231742T patent/SI2763981T1/sl unknown
- 2012-10-05 US US14/349,887 patent/US8859767B2/en active Active
- 2012-10-05 HU HUE12838558A patent/HUE048798T2/hu unknown
- 2012-10-05 CA CA2850055A patent/CA2850055C/en active Active
- 2012-10-05 CN CN201811593540.XA patent/CN110003174A/zh active Pending
- 2012-10-05 EP EP12838558.0A patent/EP2763981B1/en active Active
- 2012-10-05 MX MX2014003959A patent/MX348815B/es active IP Right Grant
- 2012-10-05 JP JP2014534478A patent/JP5805880B2/ja not_active Expired - Fee Related
- 2012-10-05 EP EP19201644.2A patent/EP3611172A1/en not_active Withdrawn
- 2012-10-05 LT LTEP12838558.0T patent/LT2763981T/lt unknown
- 2012-10-05 PL PL12838558T patent/PL2763981T3/pl unknown
- 2012-10-05 DK DK12838558.0T patent/DK2763981T3/da active
- 2012-10-05 HR HRP20200426TT patent/HRP20200426T1/hr unknown
- 2012-10-05 AU AU2012319291A patent/AU2012319291B2/en not_active Ceased
- 2012-10-05 RU RU2014117648/04A patent/RU2563630C1/ru active
- 2012-10-05 WO PCT/KR2012/008077 patent/WO2013051883A2/en not_active Ceased
- 2012-10-05 IN IN3447DEN2014 patent/IN2014DN03447A/en unknown
- 2012-10-05 PT PT128385580T patent/PT2763981T/pt unknown
- 2012-10-05 CN CN201280049302.7A patent/CN103857672B/zh active Active
- 2012-10-05 ES ES12838558T patent/ES2775197T3/es active Active
- 2012-10-05 RS RS20200295A patent/RS60118B1/sr unknown
- 2012-10-05 BR BR112014007718-5A patent/BR112014007718B1/pt not_active IP Right Cessation
-
2014
- 2014-04-03 IL IL231911A patent/IL231911B/en active IP Right Grant
-
2018
- 2018-05-29 IL IL259694A patent/IL259694B/en unknown
-
2020
- 2020-03-11 CY CY20201100214T patent/CY1122758T1/el unknown
-
2022
- 2022-03-27 IL IL291738A patent/IL291738A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX348815B (es) | Metodo para preparar clorhidrato de 1-(4-(4-(3,4-dicloro-2-fluorof enilamino)-7-metoxiquinazolin-6-iloxi)piperidin-1-il)-prop-2-en-1 -ona e intermediarios usados en el mismo. | |
| CY1121695T1 (el) | Ενωσεις και συνθεσεις ως αναστολεις κινασης c-kit | |
| UA110626C2 (uk) | Спосіб одержання пан-інгібіторів циклінзалежної кінази формули (i), а також проміжні продукти цього процесу одержання | |
| CY1122176T1 (el) | Αλατα ενος αναστολεα κινασης υποδοχεα επιδερμικου αυξητικου παραγοντα | |
| CY1121592T1 (el) | Μια στερεη μορφη της υδροχλωρικης (s)-3-(4-((4-μορφολινομεθυλ)βενζυλ)οξυ)-1-οξοϊσοϊνδολιν-2-υλ)πιπεριδινο-2,6-διονης | |
| CO6710911A2 (es) | ((r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol cristalino. | |
| CY1117197T1 (el) | Ενωσεις τριαζολοπυριδινης ως αναστολεις της κινασης ριμ | |
| BR112012007300A2 (pt) | derivador de pirimidina como inibidores proteína tirosina cinase 2 | |
| MX2020011767A (es) | Vacunas individualizadas para el cancer. | |
| CY1113778T1 (el) | Μεθοδος για την παρασκευη αμινοκροτονυλαμινο-υποκατεστημενων παραγωγων της κιναζολινης | |
| CY1114483T1 (el) | Νεα ρυθμιστικα στοιχεια | |
| CY1122132T1 (el) | Μεθοδοι για τη μειωση των ρυθμων εξαρσης του ασθματος με χρηση μπενραλιζουμαμπης | |
| PH12012501581A1 (en) | Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors | |
| CY1116823T1 (el) | Στοχευση abcb5 για θεραπεια καρκινου | |
| EA201100517A1 (ru) | Способ получения дабигатрана и его промежуточные соединения | |
| EP2521555A4 (en) | METHOD AND COMPOSITIONS FOR INCREASING SENSITIVITY AGAINST TYROSINE KINASE INHIBITORS | |
| AR088570A1 (es) | Metodos para tratar una enfermedad o trastorno relacionado con la tirosina quinasa de bruton | |
| CY1117962T1 (el) | Υδροχλωρικο αλας 4-[2-[[5-μεθυλο-1-(2- ναφθαλενυλο)-1η- πυραζολ-3-υλ]οξυ]αιθυλο] μορφολινης | |
| CY1115071T1 (el) | Συνδυασμος ο οποιος περιεχει πακλιταξελη για τη θεραπευτικη αντιμετωπιση του καρκινου των ωοθηκων | |
| WO2010099364A3 (en) | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation | |
| CY1119869T1 (el) | Αντικαρκινικος παραγοντας και μεθοδος προβλεψης θεραπευτικου αποτελεσματος για ασθενεις με κολοορθικο καρκινο μεταλλαξης kras | |
| EA201171307A1 (ru) | Антагонисты толл-подобного рецептора 3 | |
| EA201071422A1 (ru) | Способы лечения заболеваний, связанных с мейотическим кинезином | |
| UY34972A (es) | Proceso para la preparación de inhibidores de quinasa c-FMS | |
| CY1118412T1 (el) | Ν-[4-(κινολιν-4-υλοξυ)κυκλοεξυλο(μεθυλο)](ετερο)αρυλοκαρβοξα-μιδια ως ανταγωνιστες υποδοχεων ανδρογονων, παραγωγη και χρηση τους ως φαρμακευτικα προϊοντα |